These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 3918773)
1. Biologicals and biological response modifiers: new approaches to cancer treatment. Oldham RK Cancer Invest; 1985; 3(1):53-70. PubMed ID: 3918773 [No Abstract] [Full Text] [Related]
2. Biological response modifiers: their potential and limitations in cancer therapeutics. Mihich E Cancer Invest; 1985; 3(1):71-83. PubMed ID: 2578860 [No Abstract] [Full Text] [Related]
3. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer. Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660 [TBL] [Abstract][Full Text] [Related]
4. Future perspectives for biological response modifiers: a viewpoint. Mihich E Semin Oncol; 1986 Jun; 13(2):234-54. PubMed ID: 2424090 [No Abstract] [Full Text] [Related]
5. Biologicals and biological response modifiers: fourth modality of cancer treatment. Oldham RK Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy: the old and the new. Oldham RK; Smalley RV J Biol Response Mod; 1983; 2(1):1-37. PubMed ID: 6196449 [No Abstract] [Full Text] [Related]
10. Approaches to cancer therapy using biological response modifiers. MacEwen EG Vet Clin North Am Small Anim Pract; 1985 May; 15(3):667-88. PubMed ID: 2409659 [No Abstract] [Full Text] [Related]
11. Biotherapy: the fourth modality of cancer treatment. Oldham RK J Cell Physiol Suppl; 1986; 4():91-9. PubMed ID: 2427531 [TBL] [Abstract][Full Text] [Related]
12. Biologic response modifiers in the therapy of metastatic renal cell carcinoma. Quesada JR Semin Oncol; 1988 Aug; 15(4):396-407. PubMed ID: 2457256 [No Abstract] [Full Text] [Related]
13. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Lee Y; Bigner DD Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097 [TBL] [Abstract][Full Text] [Related]
14. Advances of immunotherapy of cancer: monoclonal antibodies and interferon. Foon KA Semin Oncol Nurs; 1988 May; 4(2):112-9. PubMed ID: 3131862 [No Abstract] [Full Text] [Related]
15. [Current possibilities in immunotherapy of cancer]. von Fliedner V Schweiz Med Wochenschr; 1987 Feb; 117(7):243-8. PubMed ID: 3551061 [TBL] [Abstract][Full Text] [Related]
16. Biological Response Modifiers Programme and cancer chemotherapy. Oldham RK Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193 [TBL] [Abstract][Full Text] [Related]
17. [Present status of studies on the application of immunology to the diagnosis and therapy of cancer, with emphasis on monoclonal antibodies and cytokines]. Tokunaga T Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1358-66. PubMed ID: 3296954 [TBL] [Abstract][Full Text] [Related]
18. Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers. Talmadge JE; Chirigos MA Springer Semin Immunopathol; 1985; 8(4):429-43. PubMed ID: 3879016 [No Abstract] [Full Text] [Related]
19. NIH conference. Immunomodulators in clinical medicine. Fauci AS; Rosenberg SA; Sherwin SA; Dinarello CA; Longo DL; Lane HC Ann Intern Med; 1987 Mar; 106(3):421-33. PubMed ID: 2433978 [TBL] [Abstract][Full Text] [Related]